Also Known As: Pembrolizumab, MK-3475, lambrolizumab, Keytruda

Pembrolizumab (formerly MK-3475 and lambrolizumab, trade name Keytruda[1]) is a human antibody used in cancer immunotherapy. It targets the programmed cell death 1(PD-1) receptor.[2] The drug was initially used in treating metastatic melanoma.[3][4]

Pembrolizumab was invented by Gregory Carven, Hans van Eenennaam and John Dulos at Organon Biosciences which later became Schering Plough Research Institute and then Merck & Co.[5] MRC Technology humanized the antibody pembrolizumab for Organon in 2006.

On September 4, 2014 the US Food and Drug Administration (FDA) approved pembrolizumab under the FDA Fast Track Development Program. It is approved for use following treatment with ipilimumab, or after treatment with ipilimumab and a BRAF inhibitor in advanced melanoma patients who carry a BRAF mutation.[6] It is marketed byMerck.

Print this Page

All Treatments

Average Effectiveness

This is the Average effectiveness per ailment as reported by our participants (you).

  • 0 = No improvement or Worse
  • 1 = Slight improvement
  • 2 = Moderate Improvement
  • 3 = Significant Improvement
  • 4 = Cured

Order By

Type of Treatment

Date Range

Minimum Number of Users

Complete a survey on Pembrolizumab to help the CureCrowd community

If you have tried to treat this ailment, please complete the following form to help us better our data, and help guide people to the best possible treatments. CureCrowd is a public resource with absolutely no vested interest in the outcomes of our studies.